Speaker Profile
RPh, CCN, DHPh, Founder of Metabolic Code Enterprises, TrueBinding
Biography
James LaValle is a globally recognized clinical pharmacist, author, and board-certified nutritionist with over 40 years of experience in precision health and integrative care. Founder of Metabolic Code Enterprises, he developed a cloud-based platform to identify metabolic health roadblocks. LaValle served as faculty at the University of Cincinnati College of Pharmacy and the George Washington School of Medicine, among others.He is Clinical Co-Chair at the American Academy of Anti-Aging Medicine and Chair of the International Peptide Society. LaValle has advised elite organizations like the Orlando Magic, Chicago Blackhawks, and Golden State Warriors on performance and recovery. Former Clinical Director for the Pro Football Hall of Fame Performance Health Program, he also educates first responders and military on recovery programs.Author of over 26 books, including Cracking the Metabolic Code, LaValle is Chief Science Officer at Life Time, leading its longevity and performance program, MIORA.
Talk
Galectin-3: Target to Reverse Decline of All Dementias
The presentation, "Galectin-3: The Potential Target to Reverse Decline of All Dementias" by James LaValle, explores the critical role of Galectin-3 in neuroinflammation, its association with chronic diseases, and its impact on dementia progression. It highlights groundbreaking findings on Galectin-3's mechanisms, therapeutic targets, and emerging treatments like TB006, aiming to advance dementia care.
Emerging Therapeutics Showcase:
TrueBinding
The Metabolic Code is a proprietary clinical assessment approach bridging practitioners and patients to address self-care and lifestyle goals. Its supplements target the 5 TRIADS, addressing specific metabolic imbalances identified through personalized reports, fostering health transformation and aspirational living.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy
